Dermavant Sciences: Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference

- Patient satisfaction results from tapinarof long-term extension study for the treatment of plaque psoriasis in adults to be presented - Dermavant Sciences, a clinical-stage biopharmaceutical company

Related Keywords

United States ,Koloa ,Hawaii ,America ,Sandy Johnson ,Paul Yamauchi ,Laurence Watts ,Annam Tallman ,Neal Bhatia ,Angela Salerno Robin ,Kostenloser Wertpapierhandel ,Angelay Moore ,Roivant Sciences ,Program For Tapinarof ,Twitter ,Drug Administration ,Dermavant Sciences ,Linkedin Dermavant Sciences ,Clinical Dermatology Conference ,New Drug Application ,Prescription Drug User Fee Act ,Poster Gallery ,Grand Promenade ,Grand Hyatt Kauai ,Patient Satisfaction ,Tapinarof Cream ,Once Daily ,Plaque Psoriasis ,Long Term Extension ,Patient Satisfaction Questionnaire ,Jerry Bagel ,Linda Stein Gold ,James Del Rosso ,North America ,Vice President ,Media Relations ,Dermavant ,Ciences ,Present ,Data ,Rom ,Hase ,Soaring ,Program ,022 ,Winter ,Linical ,Ermatology ,Conference ,